Although either KDM1A knockdown or doxorubicin treatment alone resulted in partial tumor regression, combined KDM1A knockdown with doxorubicin treatment was able to further inhibit tumor growth (Figure 3C-E). The gene discussed is KDM1A; the disease is neoplasm.